Further longitudinal studies are required to clarify whether IP-10 is a clinically useful biomarker for the development of type 2 diabetes and a therapeutic target in patients with NAFLD. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatotic liver disease.